GSK Reports the P-III Study Results of Nucala (Mepolizumab) for Treating Chronic Obstructive Pulmonary Disease (COPD)
Shots:
- GSK reported headline results from P-III (MATINEE) study to assess the effectiveness of Nucala (IL-5 targeting mAb) vs PBO in reducing moderate or severe exacerbations as an add-on to optimized therapy in COPD patients (n=806) for over 52wks., max 104wks.
- The study reached its 1EP, demonstrating significantly reduced annualised rate of moderate/severe exacerbations with Nucala in addition to maintenance therapy vs PBO post 104wks.
- The safety profile was similar to the previous outcomes. Further analysis is underway and full data will be highlighted at upcoming conferences & shared with regulatory authorities
Ref: GSK | Image: GSK
Related News:- GSK’s Nucala (Mepolizumab) Receives Japanese Approval for Treating Chronic Rhinosinusitis with Nasal Polyps
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
